359 related articles for article (PubMed ID: 33075136)
1. Impaired natural killer cell counts and cytolytic activity in patients with severe COVID-19.
Osman M; Faridi RM; Sligl W; Shabani-Rad MT; Dharmani-Khan P; Parker A; Kalra A; Tripathi MB; Storek J; Cohen Tervaert JW; Khan FM
Blood Adv; 2020 Oct; 4(20):5035-5039. PubMed ID: 33075136
[TBL] [Abstract][Full Text] [Related]
2. Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent.
Mazzoni A; Salvati L; Maggi L; Capone M; Vanni A; Spinicci M; Mencarini J; Caporale R; Peruzzi B; Antonelli A; Trotta M; Zammarchi L; Ciani L; Gori L; Lazzeri C; Matucci A; Vultaggio A; Rossi O; Almerigogna F; Parronchi P; Fontanari P; Lavorini F; Peris A; Rossolini GM; Bartoloni A; Romagnani S; Liotta F; Annunziato F; Cosmi L
J Clin Invest; 2020 Sep; 130(9):4694-4703. PubMed ID: 32463803
[TBL] [Abstract][Full Text] [Related]
3. Natural killer cell immunotypes related to COVID-19 disease severity.
Maucourant C; Filipovic I; Ponzetta A; Aleman S; Cornillet M; Hertwig L; Strunz B; Lentini A; Reinius B; Brownlie D; Cuapio A; Ask EH; Hull RM; Haroun-Izquierdo A; Schaffer M; Klingström J; Folkesson E; Buggert M; Sandberg JK; Eriksson LI; Rooyackers O; Ljunggren HG; Malmberg KJ; Michaëlsson J; Marquardt N; Hammer Q; Strålin K; Björkström NK;
Sci Immunol; 2020 Aug; 5(50):. PubMed ID: 32826343
[TBL] [Abstract][Full Text] [Related]
4. Clinical Characteristics and Immune Injury Mechanisms in 71 Patients with COVID-19.
Wu Y; Huang X; Sun J; Xie T; Lei Y; Muhammad J; Li X; Zeng X; Zhou F; Qin H; Shao L; Zhang Q
mSphere; 2020 Jul; 5(4):. PubMed ID: 32669467
[TBL] [Abstract][Full Text] [Related]
5. Flattening the COVID-19 Curve With Natural Killer Cell Based Immunotherapies.
Market M; Angka L; Martel AB; Bastin D; Olanubi O; Tennakoon G; Boucher DM; Ng J; Ardolino M; Auer RC
Front Immunol; 2020; 11():1512. PubMed ID: 32655581
[TBL] [Abstract][Full Text] [Related]
6. COVID-19 pneumonia: CD8
Jiang Y; Wei X; Guan J; Qin S; Wang Z; Lu H; Qian J; Wu L; Chen Y; Chen Y; Lin X
Clin Immunol; 2020 Sep; 218():108516. PubMed ID: 32574709
[TBL] [Abstract][Full Text] [Related]
7. Pro- and Anti-Inflammatory Responses in Severe COVID-19-Induced Acute Respiratory Distress Syndrome-An Observational Pilot Study.
Notz Q; Schmalzing M; Wedekink F; Schlesinger T; Gernert M; Herrmann J; Sorger L; Weismann D; Schmid B; Sitter M; Schlegel N; Kranke P; Wischhusen J; Meybohm P; Lotz C
Front Immunol; 2020; 11():581338. PubMed ID: 33123167
[TBL] [Abstract][Full Text] [Related]
8. Immune dysfunction following COVID-19, especially in severe patients.
Song CY; Xu J; He JQ; Lu YQ
Sci Rep; 2020 Sep; 10(1):15838. PubMed ID: 32985562
[TBL] [Abstract][Full Text] [Related]
9. The Potential Effect of Novel Coronavirus SARS-CoV-2 on NK Cells; A Perspective on Potential Therapeutic Interventions.
Jewett A
Front Immunol; 2020; 11():1692. PubMed ID: 32754162
[TBL] [Abstract][Full Text] [Related]
10. Severe COVID-19: what have we learned with the immunopathogenesis?
Bordallo B; Bellas M; Cortez AF; Vieira M; Pinheiro M
Adv Rheumatol; 2020 Sep; 60(1):50. PubMed ID: 32962761
[TBL] [Abstract][Full Text] [Related]
11. Single-cell landscape of immunological responses in patients with COVID-19.
Zhang JY; Wang XM; Xing X; Xu Z; Zhang C; Song JW; Fan X; Xia P; Fu JL; Wang SY; Xu RN; Dai XP; Shi L; Huang L; Jiang TJ; Shi M; Zhang Y; Zumla A; Maeurer M; Bai F; Wang FS
Nat Immunol; 2020 Sep; 21(9):1107-1118. PubMed ID: 32788748
[TBL] [Abstract][Full Text] [Related]
12. Clinical and Immune Features of Hospitalized Pediatric Patients With Coronavirus Disease 2019 (COVID-19) in Wuhan, China.
Wu H; Zhu H; Yuan C; Yao C; Luo W; Shen X; Wang J; Shao J; Xiang Y
JAMA Netw Open; 2020 Jun; 3(6):e2010895. PubMed ID: 32492165
[TBL] [Abstract][Full Text] [Related]
13. Prediction Model Based on the Combination of Cytokines and Lymphocyte Subsets for Prognosis of SARS-CoV-2 Infection.
Luo Y; Mao L; Yuan X; Xue Y; Lin Q; Tang G; Song H; Wang F; Sun Z
J Clin Immunol; 2020 Oct; 40(7):960-969. PubMed ID: 32661797
[TBL] [Abstract][Full Text] [Related]
14. Friends or foes? The knowns and unknowns of natural killer cell biology in COVID-19 and other coronaviruses in July 2020.
Manickam C; Sugawara S; Reeves RK
PLoS Pathog; 2020 Aug; 16(8):e1008820. PubMed ID: 32845937
[TBL] [Abstract][Full Text] [Related]
15. Perforin and resistance to SARS coronavirus 2.
Cunningham L; Simmonds P; Kimber I; Basketter DA; McFadden JP
J Allergy Clin Immunol; 2020 Jul; 146(1):52-53. PubMed ID: 32422144
[No Abstract] [Full Text] [Related]
16. SARS-CoV-2 Spike 1 Protein Controls Natural Killer Cell Activation via the HLA-E/NKG2A Pathway.
Bortolotti D; Gentili V; Rizzo S; Rotola A; Rizzo R
Cells; 2020 Aug; 9(9):. PubMed ID: 32859121
[TBL] [Abstract][Full Text] [Related]
17. Natural Killer Cell Dysfunction and Its Role in COVID-19.
van Eeden C; Khan L; Osman MS; Cohen Tervaert JW
Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32883007
[TBL] [Abstract][Full Text] [Related]
18. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.
Zhang X; Zhang Y; Qiao W; Zhang J; Qi Z
Int Immunopharmacol; 2020 Sep; 86():106749. PubMed ID: 32645632
[TBL] [Abstract][Full Text] [Related]
19. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome.
Weiskopf D; Schmitz KS; Raadsen MP; Grifoni A; Okba NMA; Endeman H; van den Akker JPC; Molenkamp R; Koopmans MPG; van Gorp ECM; Haagmans BL; de Swart RL; Sette A; de Vries RD
Sci Immunol; 2020 Jun; 5(48):. PubMed ID: 32591408
[TBL] [Abstract][Full Text] [Related]
20. Assessing SARS-CoV-2 RNA levels and lymphocyte/T cell counts in COVID-19 patients revealed initial immune status as a major determinant of disease severity.
Han M; Xu M; Zhang Y; Liu Z; Li S; He T; Li J; Gao Y; Liu W; Li T; Chen Z; Huang X; Cheng G; Wang J; Dittmer U; Witzke O; Zou G; Li X; Lu M; Zhang Z
Med Microbiol Immunol; 2020 Dec; 209(6):657-668. PubMed ID: 32860073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
